OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 3,415 JAZZ derivative securities | OQRO

Home
Insider trades
Jazz Pharmaceuticals
Director exercised or converted 3,415 JAZZ derivative securities

Insider trades

Insider trade

Director exercised or converted 3,415 JAZZ derivative securities

Traded May 22, 2026 · Filed May 28, 2026

JAZJazz PharmaceuticalsJAZZ

3,415
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 22, 2026
Reporting period: Not applicable
Filed with the SEC: May 28, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001302443-26-000008

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

May 28, 2026, 2:13 AM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Jazz Pharmaceuticals plc

Issuer CIK

1232524

Ticker

JAZZ

Reporting person

Rick E Winningham

Relationship

Director

Security

Non-Qualified Stock Option (right to buy)

Table

Derivative (Table II)

Transaction date

May 22, 2026

Transaction code

Shares / units

3,415

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017.

Around the same time

Mark Douglas Smith (Director) sold ~$267K of Jazz Pharmaceuticals

Scheduled in advanceFiled 4mo ago

Neena M Patil (EVP & Chief Legal Officer) sold ~$278K of Jazz Pharmaceuticals

Scheduled in advanceFiled 4mo ago

Renee D GalaPresident & CEO

Filed 4mo ago

600Shares

Traded Jun 3 · filed 3 days later

Gift or transfer — classified separately from trades.

More Official record